Okay. Good afternoon, everyone, and thank you for attending our conference today. I'm Susan Anderson, one of Canaccord's analysts in the consumer space. We're very excited to have here BioHarvest, and in particular, CEO and co-founder, Dr. Zaki Rakib. With that, I'll turn it over to Dr. Zaki to go over BioHarvest. Well, thanks. I guess I should hope for next year, the room will be packed. But I'm happy to have you guys here. My name is Zaki Rakib. I'm the Chief Executive Officer of BioHarvest. I'm also the Executive Chairman. I'm also one of the large investors in the company. I invested about $18 million of my own money. We love to call ourselves the industrial plant cell culture company because we're a biotech company. We're a CDMO. We've developed a horizontal technology. By horizontal, I mean it's a platform technology that is capable of catering to multiple industries. What we do very well, better than anyone else, is to grow the ingredients, grow the molecules that are inside the plants, inside the cells of the plant, without growing the plant itself. So as much as it sounds like magic, it is magic. We don't do any genetic modification, but we're able to get the cells of the plant to express better the molecules they have inside them. I am blessed to have a strong leadership team. Some of the people here have been with us for over 15 years, covering all disciplines needed for the company to be very successful. We were incorporated in 2007. We spent a little over $100 million in developing this unique platform technology, which has been manifested in a product that we have been able to develop and bring it to the market. But mainly it is the platform technology for which we've built a factory with a capacity of 20 tons. We have about 15 patents that we have registered with the process technology and some of the unique compositions that we've created that are all cell based. On the CDMO side, which is what the company is, I like to talk about the company in terms of a forest that is capable of producing a lot of trees. We have one tree that we're selling right now, which is one product that we are selling directly to the market. But the essence of the company is a CDMO, and we're going to be able to produce more trees, some of which are trees that have customers. By trees, I don't mean literally, although some of the products come from trees. We have two molecules that we're developing for Tate & Lyle, which was recently was acquired by Ingredion, together a $10 billion company. We have a product based on saffron, and we have a product for the fragrance industry, a luxury high-end fragrance industry of about $15 billion. We just announced its agreement yesterday. It is a 20 tons agreement covering 2027 and 2028 with a value between $20 million and $30 million. What are those industries I mentioned looking for when they deal with natural-based products? They want products that are efficacious. They want products that are natural. The economics work for them, and they want also sustainability. For that purpose, if they are looking for molecules, nature itself is not an industrial supply chain to support that quest. What we have brought to all those industries is the controlled industrial biology. We apply what we call programmable biology, programmable cell biology, to be able to force the cell to express the ingredients that the customer we are interested in, the healthy or active ingredients. With that, we are able to deal with the inconsistency. From batch to batch, we are consistent, unlike nature. Two bananas growing adjacent to each other will express materials differently. We are not affected by climate, we are not affected by land, we are not affected by any geopolitical situation. Plants or the plant ingredients, those molecules grow inside large-scale bioreactors, which is one of the unique features that we bring. I said earlier, the stack starts with programmable plant biology, using the cell culture as the underlying technology, which produce what we call precision botanicals. Why they are precision, because again, they are consistent from batch to batch. Once we lock the cell bank of any particular plant, we are now ready to produce perpetually the same ingredients without any genetic mutation or anything like that. We do that in large-scale bioreactors that are scalable. The business model is we develop, we produce, we sell, we get also royalties. Briefly how the technology works, we take only a piece of this plant. We are not an agriculture company. We do not plant anything. We just take a piece of that plant or fruit, and then we apply our technology, which is the programmable cell biology. We apply conditions, and we force the cells to exhibit or to express what we want them more than others. For example, the product that we sold last year for $33 million based on red grape. The one particular ingredient called Piceid resveratrol is amplified 100 times more than in nature, and without the sugar. We can get in one capsule of 400 mg, the equivalent of 1,000 grapes or a whole bottle of red wine without the alcohol or without the sugar. Once we have locked the cell bank, now we guarantee the consistency. Usually, the first step is, in any new product that we develop, that would be the one with the highest risk. But once it is done, now we can produce perpetually. The cycle is three weeks. It goes from small-scale bioreactor, where we propagate the cells, all the way to large-scale ones. What we collect is basically we harvest mud, which contains those cells, and we dry them, and then you can do whatever you want with a powder. You can put it in capsules; you can add it to other ingredients and basically package it in whichever way you wanted the product. For validation of our process technology, we actually brought to the market this product called VINIA, which is based on red grape cells. We have conducted clinical trials for that particular product to prove the efficacy of it, but also to prove the economics and prove the scalability of our technology. Once again, the technology benefits of using cell culture and using our botanical synthesis technology is the scalability, predictability, because you can predict upfront what would be the composition, and it is done fairly fast. Lower cost, more potency in the molecules. I mentioned earlier the ability to magnify the ingredients, bioavailability because of the naturality, and a lot of our molecule are glycosides, so they are better to traverse the intestines. We have controlled consistency. What is very interesting for our customers and for ourselves, that any composition we have is patent protected. It is very important because nature cannot produce the same composition. We do not change the conformation of the molecules. We are not applying any genetic modification. But the composition is different because the ratio between the different ingredients is completely different than what nature. You need one over 100 billion of likelihood to have nature producing the exact same composition. From a patent perspective, when you have a composition connected to a process and to a utility, you have a very solid patent. In the last three years, we have been investing heavily in AI, not only for the discovery part, but for the machine learning, because every time we develop a new product, think about it, that we make tens of thousands of experiments. We learn from those experiments, and we can apply the learning from those experiments on the other products. Ultimately, as a CDMO, we want to be able to process as many products simultaneously for development purpose, and after that, of course, for manufacturing purpose as we continue to build capacity. The AI is not only for machine learning purpose, it is also a tool for discovery and for validation of the molecule binding to the receptors of the body if the end goal is to have something related to health and wellness. We are developing, and we have already the first version of the testing to see if we are going to develop a new molecule. We want to see how well it binds into the receptor for whatever indication we are looking at. What we currently have in terms of assets, VINIA is this first molecule where you see on the left, the piceid resveratrol enhancement of 100x over what is in nature. The other one that we have developed is olives and pomegranate with 15x. The verbascoside is one of the most important molecules that is in the olive product. For the pomegranate, the PGG. Each one of them corresponds to a certain indication. The case of verbascoside, for example, it is well known to be effective with non-alcoholic fatty liver disease. The other four projects on the right, these are projects we do for customers, but we are retaining some of the equity in those molecules. The one that we have announced yesterday, the $20 million to $30 million deal, 2027 and 2028 is the one with this rare fragrance, which we retain 20% ownership of the molecule. Interesting enough, the type of molecules in this particular fragrance coming from a very exotic tree, it's the sesquiterpenes and the chromones are common also with some other type of fragrances that are produced in other exotic trees and are well regarded. The two molecules for Tate & Lyle are protein from fruits growing in Africa. The third category, the other category, the carotenoids that exist with the saffron, which can, as an application, saffron can go for culinary applications, it can go for dietary supplement application, and also for fragrance application. In that particular product, we retain 25% ownership. The typical molecules of the safranal, crocins, and picrocrocins, all of which are manifested and expressed in the compositions that we've developed. If you look at the stage where each and every molecule, many of them are already in advanced stage, and we will expect to start manufacture more than just VINIA next year. We have the fragrance. We'll be manufacturing also some of the saffron. The year after, we'll have five different products that we'd be manufacturing. The new manufacturing site is going to be commissioned in the end of 2027, and we expect to start production in early 2028. Something happened to the remote. Can you take a look? It's not responding. In the meantime, once again, the business model of the CDMO is we either have our own molecules that we develop independently, and we offer them as part of the menu when we engage with customers on all different four industries, pharma, nutraceuticals, cosmeceuticals, and nutrition. Then once we sign an agreement for development, either it's at something that we're already at an advanced stage of development. Okay. Good, thanks. Then from development, usually it's 18 to 24 months to move into manufacturing. We just started the CDMO business in 2025. We did $2 million in revenue. Again, not the revenue coming from the product VINIA, which is what you have here in front of you, which we did about $33 million last year. Cumulatively, over $100 million. It's one grape. Once again, we don't do any agriculture. We don't go to the vineyards. Just one grape that we cloned, we took the cells from, and from that point, we kept the perpetual process of propagating the cells. Particularly, that product is unique in the sense that it has gone through clinical trials. We sell it directly on our website, vinia.com, and on Amazon. About 20% of the revenue comes from Amazon. What's special about this product and the Piceid resveratrol, which is a molecule that is not synthesizable chemically. What's unique about it is that it improves blood flow by increasing the ability of the body to produce nitric oxide, which is a vasodilator, and reduce the amount of production of ET1, endothelin-1, which is a vasoconstrictor. As I said, just this one tree from a forest that is capable of producing many of them. This one in particular, we use as the validation to the technology, and it's been very useful to be able to attract the customers that we have on the CDMO. The goals for 2026 is to achieve $4 million to $5 million in revenue from the CDMO, all of which will be development. Next year, we're going to see revenue coming from development and from manufacturing with the product that I mentioned earlier for the fragrance, for which we have already signed an agreement. Just diving a little bit into that particular fragrance. This is amazing what nature does to tree that, after five years of growth, gets attacked by a fungus. The tree reacts to that fungus by producing those sesquiterpenes and chromones molecules that, when get heated over a charcoal or whatever, they generate the smell. It's either it's used for incense or you can produce oil, and that oil is the base or the raw material for producing fragrances. A lot of the high-end fragrance designers are using this particular material. We're not at ease to disclose it because we're under a non-disclosure agreement, but it's easy for you to look at which ingredients has $15 billion of market on an annual basis and which one is used in the Arabian Gulf or Persian Gulf or whatever you call it. If you look at similar opportunities in fragrances, it's amazing. It's just the beginning, and I can tell you, I already got a call this morning after we announced the deal of people that are interested in developing fragrances using some of the other ingredients. You could see what sandalwood oil, for example, price or the orris absolute, $70,000 per kilogram of oil. The economics and the margins there are substantial and very healthy for BioHarvest. I mentioned that earlier. We're catering to four different industries, so we have this horizontal ability to address. We're not waiting. Unlike CDMO that only focus on pharma, we don't have to wait for a molecule to get through all the approval of the FDA. For example, fragrance, there's no regulatory hurdles. Same thing for nutrition. There's small regulatory hurdles for nutraceuticals and way less for cosmetics. I mentioned earlier the business model. Development. We've added on the development discovery. We're in early stages. I mentioned the model with the binding to guarantee that whatever molecule is going to bind to whatever receptor you plan to have that, and part of the deal is to get royalties on the molecules that we develop. Currently, we're building the second factory. We've raised money in November of last year, sufficient to have the ability to continue with the operations but building the second factory currently based in Israel. In 2029 and beyond, we're looking at building capacity in the U.S. Part of the building capacity in the U.S. can be done by the customers themselves. If a customer like Tate & Lyle is planning to have 50 tons a year or more, it makes sense for me to license them the technology to build a factory at their own nickel and then collect royalties. But because each bioreactor is a unique engine, I can mix and match because the same platform technology on the same floor, I can have 5, 10, or 20 different products at various capacities running simultaneously through the production floor. I mentioned earlier the guidance. The one in the middle includes if you were to separate the CDMO from the D2C from VINIA, revenue this year would be on the CDMO between $12 million and $14 million because the transaction intercompany that I produce the powder for the D2C business that can then sell is sold directly to consumer. Consolidated revenue guidance is $37 million to $40 million. We are projecting next year, higher revenue on both, but with EBITDA profitability next year. Again, we're going to be spending money in the next 18 months, not only on building the factory, but spending money on technology. We received some grants from the Israel Innovation Authority, mostly in AI and computer vision. We can reduce the number of experiments by using computer vision capabilities that can detect what's inside the cells. I don't need microscopes, and I don't need a lot of people to be able to cater to each and every Petri dish among the thousands that we're developing in every cycle. With that, I want to thank you for your attention. I don't know if there's any questions. We have four minutes. Am I right? Is that four minutes? Any questions? Thank you.